Effect of phosphodiesterase-5 inhibition on SystEmic Right VEntricular size and function. A multicentre, double-blind, randomized, placebo-controlled trial: SERVE.

Publikation

Effect of phosphodiesterase-5 inhibition on SystEmic Right VEntricular size and function. A multicentre, double-blind, randomized, placebo-controlled trial: SERVE.

Wissenschaftlicher Artikel/Review - 13.06.2023

Greutmann Matthias, Tobler Daniel, Engel Reto, Heg Dik, Mueller Arndt-Christian, Frenk André, Gabriel Harald, Rutz Tobias, Buechel Ronny Ralf, Willhelm Matthias, Trachsel Lukas, Freese Michael, Ruperti-Repilado Francisco Javier, Valsangiacomo Buechel Emanuela, Beitzke Dietrich, Haaf Philip, Wustmann Kerstin, Schwitz Fabienne, Possner Mathias, Schwitter Juerg, Bouchardy Judith, Schwerzmann Markus, SERVE Investigators

Zitation

Greutmann M, Tobler D, Engel R, Heg D, Mueller A, Frenk A, Gabriel H, Rutz T, Buechel R, Willhelm M, Trachsel L, Freese M, Ruperti-Repilado F, Valsangiacomo Buechel E, Beitzke D, Haaf P, Wustmann K, Schwitz F, Possner M, Schwitter J, Bouchardy J, Schwerzmann M, SERVE Investigators. Effect of phosphodiesterase-5 inhibition on SystEmic Right VEntricular size and function. A multicentre, double-blind, randomized, placebo-controlled trial: SERVE. Eur J Heart Fail 2023; 25:1105-1114.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Eur J Heart Fail 2023; 25

Veröffentlichungsdatum

13.06.2023

eISSN (Online)

1879-0844

Seiten

1105-1114

Kurzbeschreibung/Zielsetzung

In adults with congenital heart disease and systemic right ventricles, progressive right ventricular systolic dysfunction is common and is associated with adverse outcomes. Our aim was to assess the impact of the phosphodiesterase-5-inhibitor tadalafil on right ventricular systolic function.